Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Doctoral School of Health Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Chem Biol Interact. 2023 Nov 1;385:110749. doi: 10.1016/j.cbi.2023.110749. Epub 2023 Oct 5.
We aimed to investigate serum amino-terminal C-type natriuretic peptide (NT-proCNP) and its relationship with quantitative and qualitative HDL-parameters in patients with end-stage renal disease (ESRD) before, then 1 and 6 months after kidney transplantation (TX). Seventy patients (47 males, 23 females, mean age 51.7 ± 12.4 years) were enrolled in a prospective follow-up study. We examined serum creatinine, C-reactive protein, procalcitonin, fasting glucose and lipid parameters before, then 1 and 6 months after TX. High-density lipoprotein- (HDL)-associated paraoxonase-1 (PON1) paraoxonase and arylesterase activities were measured spectrophotometrically. Lipoprotein subfractions were determined by Lipoprint. NT-proCNP and oxidized low-density lipoprotein (oxLDL) levels were measured by ELISA. Mean NT-proCNP was 45.8 ± 21.9 pmol/L before renal transplantation and decreased markedly 1 month and 6 months after transplantation (5.3 ± 2.5 and 7.7 ± 4.9 pmol/L, respectively, P = 1 × 10). During the 6 months' follow-up, PON1 arylesterase, paraoxonase and salt-stimulated paraoxonase activities improved. NT-proCNP positively correlated with procalcitonin and creatinine and negatively with GFR, LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C). There was a negative correlation between serum NT-proCNP and PON1 arylesterase activity. According to the multiple regression analysis, the best predicting variables of NT-proCNP were serum procalcitonin, creatinine and PON1 arylesterase activity. NT-proCNP might be a novel link between HDL dysfunction and impaired vascular function in ESRD, but not after kidney transplantation. Further studies in larger populations are needed to clarify the exact role of NT-proCNP in the risk prediction for cardiovascular comorbidities and complications in ESRD.
我们旨在研究终末期肾病(ESRD)患者肾移植(TX)前、后 1 个月和 6 个月的血清氨基末端 C 型利钠肽(NT-proCNP)及其与定量和定性高密度脂蛋白(HDL)参数的关系。70 例患者(47 名男性,23 名女性,平均年龄 51.7±12.4 岁)被纳入前瞻性随访研究。我们检测了 TX 前、后 1 个月和 6 个月的血清肌酐、C 反应蛋白、降钙素原、空腹血糖和血脂参数。采用分光光度法测定高密度脂蛋白(HDL)相关的对氧磷酶-1(PON1)对氧磷酶和芳基酯酶活性。脂蛋白亚组分采用 Lipoprint 测定。采用 ELISA 测定 NT-proCNP 和氧化型低密度脂蛋白(oxLDL)水平。肾移植前平均 NT-proCNP 为 45.8±21.9 pmol/L,移植后 1 个月和 6 个月显著下降(分别为 5.3±2.5 和 7.7±4.9 pmol/L,P=1×10)。在 6 个月的随访中,PON1 芳基酯酶、对氧磷酶和盐刺激对氧磷酶活性得到改善。NT-proCNP 与降钙素原和肌酐呈正相关,与 GFR、LDL-胆固醇(LDL-C)和 HDL-胆固醇(HDL-C)呈负相关。血清 NT-proCNP 与 PON1 芳基酯酶活性呈负相关。根据多元回归分析,NT-proCNP 的最佳预测变量是血清降钙素原、肌酐和 PON1 芳基酯酶活性。NT-proCNP 可能是 ESRD 中 HDL 功能障碍和血管功能受损之间的新联系,但不是在肾移植后。需要在更大的人群中进行进一步的研究,以阐明 NT-proCNP 在 ESRD 心血管合并症和并发症风险预测中的确切作用。